DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Anti-CD22 Immunotherapeutics in: October 2016 R&D and Business Tracker for Antibody-Drug Conjugates" report to their offering.
Anti-CD22 Immunotherapeutics in: October 2016 R&D and Business Tracker for Antibody-Drug Conjugates
This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of October 2016. This issue forms part of the subscription service R&D and Business Tracker for Antibody-Drug Conjugates.
Featured presentations of October 2016 include the pipeline of CD22-targeted immunotherapeutics, the profile of US biotech Asana Biosciences and the profile of anti-nectin-6 antibody-drug conjugate AGS67E from Astellas Pharma.
The October 2016 issue of our R&D and Business Tracker service about antibody-drug conjugates contains:
R&D and Technology Tracker
- Pipeline changes
- Regulatory news
- Technology validations
- Manufacturing news
Business Tracker for:
- Company updates
- Merger & acquisitions
Clinical Trial Tracker
Scientific Publication Tracker
Featured ADC Profile: AGS67E
Featured Company Profile: Asana Biosciences
Featured Target Pipeline: Anti-CD22 Immunotherapeutics
CD-22 Targeted Immunotherapeutics include:
- Naked Antibodies & Combinations
- Antibody-Drug Conjugates
- Autologous CAR T-Cells
Information about the anti-CD22 Immunotherapeutics pipeline is provided in a tabular format and fully referenced.
For more information about this report visit http://www.researchandmarkets.com/research/vnr2vp/anticd22